Importantly, in the AMPLPIFY-EXT trial the bleeding rate with apixaban 2.5 mg twice daily was similar to that of placebo (Figure 25)[14]– a remarkable finding that makes this low dose of apixaban very attractive during long-term treatment.  Apixaban 5 mg twice daily dose also produced very attractive results, but there was a small increase in bleeding with the 5 mg compared with the 2.5 mg twice daily dose.  Eikelboom J. Am J Med 2013; published on-line at http://education.amjmed.com/00000.